Results 11 to 20 of about 160,652 (313)

ANCA associated vasculitis subtypes: Response (response to letter) [PDF]

open access: yes, 2022
Many thanks for the opportunity to respond to the interesting letter to the Editor from Merkel, Jayne, and Bekker, with regard to our publication “ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives”.1In the management section of
Robson, Joanna C   +6 more
core   +1 more source

Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders

open access: yesBMC Women's Health, 2021
Background Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyoderma ...
Laura Yockey   +8 more
doaj   +1 more source

Reuma.pt/vasculitis – the Portuguese vasculitis registry [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2020
AbstractBackgroundThe vasculitides are a group of rare diseases with different manifestations and outcomes. New therapeutic options have led to the need for long-term registries. The Rheumatic Diseases Portuguese Register, Reuma.pt, is a web-based electronic clinical record, created in 2008, which currently includes specific modules for 12 diseases and 
Ponte, Cristina   +33 more
openaire   +5 more sources

Diagnostic delays in vasculitis and factors associated with time to diagnosis

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Patients with vasculitis, a set of rare diseases, encounter delays in obtaining an accurate diagnosis which can lead to substantial morbidity and increased mortality.
Antoine G. Sreih   +9 more
doaj   +1 more source

[Cocaine-induced vasculitis and mimics of vasculitis]. [PDF]

open access: yes, 2023
Cocaine is a psychotropic tropane alkaloid and stimulant drug. Nasal insufflation of cocaine powder is a common route of administration. In Germany, cocaine is frequently adulterated with levamisole, an anthelminthic drug with immunomodulatory effects ...
Holl-Ulrich, Konstanze   +4 more
core   +1 more source

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

open access: yesTrials, 2023
Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms.
Mark E. McClure   +13 more
doaj   +1 more source

Introduction to the PANLAR Guidelines: Giant Cell Arteritis

open access: yesGlobal Rheumatology, 2022
Introduction to the PANLAR Guidelines: Giant Cell Arteritis Dr. Sebastián Unizony describes how the process of construction and consolidation of this document by a team of experts was.
Sebastian Unizony
doaj   +1 more source

Immune-Complex Allergic Vasculitis in Association with the Immune-Complex Allergic Vasculitis in Association with the Development of Transverse Myelitis: A Case Report [PDF]

open access: yes, 1996
A severe vasculitis, probably therapy related, in a sixty-four-year-old man being treated for possible subacute bacterial endocarditis, was associated with the development of transverse myelitis.
Huehns, Tanya Y.   +7 more
core   +1 more source

An Atypical Case of Hepatitis B-Associated Vasculitis [PDF]

open access: yes, 2023
One of the many extra-hepatic manifestations of hepatitis B virus (HBV) infections is vasculitis. While the classic HBV-associated vasculitis is polyarteritis nodosa, other vasculitides have been reported.
Christopher S. Jenkins   +4 more
core   +1 more source

Patient involvement in medical research: what patients and physicians learn from each other

open access: yesOrphanet Journal of Rare Diseases, 2019
Background There is increasing interest in actively involving patients in the process of medical research to help ensure research is relevant and important to both researchers and people affected by the disease under study.
Kalen Young   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy